50.88
-0.915(-1.77%)
Currency In USD
| Previous Close | 51.79 |
| Open | 52.16 |
| Day High | 53.05 |
| Day Low | 50 |
| 52-Week High | 53.86 |
| 52-Week Low | 7.58 |
| Volume | 391,115 |
| Average Volume | 1.05M |
| Market Cap | 2.09B |
| PE | -14.66 |
| EPS | -3.47 |
| Moving Average 50 Days | 22.43 |
| Moving Average 200 Days | 14.39 |
| Change | -0.92 |
If you invested $1000 in Celcuity Inc. (CELC) since IPO date, it would be worth $3,560.18 as of August 18, 2025 at a share price of $50.875. Whereas If you bought $1000 worth of Celcuity Inc. (CELC) shares 5 years ago, it would be worth $9,352.02 as of August 18, 2025 at a share price of $50.875.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call
GlobeNewswire Inc.
Aug 07, 2025 11:05 AM GMT
MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second q
Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants
GlobeNewswire Inc.
Jul 30, 2025 10:30 AM GMT
MINNEAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten public offe
Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
GlobeNewswire Inc.
Jul 28, 2025 8:02 PM GMT
MINNEAPOLIS, July 28, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced proposed underwritten public offerings of $